**You are invited to attend:**

**At the Heart of It:**   
**A New Look at Clinical Cardiovascular Disease in Diabetes**

Since 2013, the Canadian Diabetes Association has recommended that healthcare providers individualize the choice of pharmacologic treatments according to patient and agent characteristics. In light of the availability of new cardiovascular outcome trial data, and their corresponding inclusion into the two 2016 CDA Guidelines Interim Updates (March and November), this program aims to help healthcare providers navigate the wealth of treatment choices available to manage type 2 diabetes. This program was designed by a multidisciplinary committee composed of family physicians, pharmacists and an endocrinologist, and utilizes case-directed learning to address multiple considerations—in particular cardiovascular disease—associated with treating patients with diabetes today.

**After attending this session, participants will be able to:**

* Review and interpret the CDA recommendations, including the November 2016 updates, for vascular protection and diabetes management in patients with type 2 diabetes, with and without cardiovascular disease.
* Summarize available cardiovascular outcome data and discuss their applicability in the primary care setting.
* Compare and contrast among individual agents within the DPP-4 inhibitor, GLP-1 receptor agonist, and SGLT2 inhibitor classes.

**Event Details**

**Location:** {Placeholder.EventVenue}

**Date:** {Placeholder.EventDate} **Dinner Time:** {Placeholder.DinnerTime} **Program Time:** {Placeholder.EventTime}

**Presenter:** {Placeholder.SpeakerModeratorDisplayName}

**Kindly RSVP to:** {Placeholder.EventOwnerFirstName} {Placeholder.EventOwnerLastName}

**At:** {Placeholder.EventOwnerPhoneNumber}or {Placeholder.EventOwnerEmail}

The Fédération des médecins omnipraticiens du Québec, a continuing education body fully accredited by the Collège des médecins du Québec, grants 1 hour of Category 1 credits to the participants in this activity. The Code of Ethics of the Conseil québécois de dévelopment professionnel continu des médecins (CQDPCM) must be respected (www.cqdpcm.ca).

This program was supported in part by an educational grant from Novo Nordisk Canada Inc.